In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

PFS and Autoinjector Drug Delivery: A Platform of Primary Packaging Solutions for Str...
Webinars, Pharmaceutical, Product Solutions, Device Innovations, Market Insights

Aptar Pharma Expands Injectables Components Manufacturing Capabilities
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Characterizing and Controlling Foreign Particulate Matters (FPM)
Webinars, Pharmaceutical, Market Insights, Product Solutions

Building Digital Solutions To Meet The Unique Therapeutic Needs of Patients
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations